Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Diabetes is a global disease that can lead to a range of complications. Currently, the treatment of type 2 diabetes focuses on oral hypoglycemic drugs and insulin analogues. Studies have shown that drugs such as oral metformin are useful in the treatment of diabetes but can limit the liver’s ability to release sugar. The development of glucose-lowering peptides has provided new options for the treatment of type 2 diabetes. Peptide drugs have low oral utilization due to their easy degradation, short half-life, and difficulty passing through the intestinal mucosa. Therefore, improving the oral utilization of peptide drugs remains an urgent problem. This paper reviews the research progress of peptide drugs in the treatment of diabetes mellitus and proposes that different types of nano-formulation carriers, such as liposomes, self-emulsifying drug delivery systems, and polymer particles, should be combined with peptide drugs for oral administration to improve their absorption in the gastrointestinal tract.
Funding Information
  • National Natural Science Foundation of China (82003985, JLPZGF-2020-107, 202310199001, 202310199051X, 20210204013YY, 20230401062YY, 20230204019YY, 20230401075YY, 2023C027-3, 2022JP06)
  • Drug Administration project of Jilin province (82003985, JLPZGF-2020-107, 202310199001, 202310199051X, 20210204013YY, 20230401062YY, 20230204019YY, 20230401075YY, 2023C027-3, 2022JP06)
  • National College Students’ innovation and entrepreneurship training program (82003985, JLPZGF-2020-107, 202310199001, 202310199051X, 20210204013YY, 20230401062YY, 20230204019YY, 20230401075YY, 2023C027-3, 2022JP06)
  • Jilin Province Science and Technology Development Project in China (82003985, JLPZGF-2020-107, 202310199001, 202310199051X, 20210204013YY, 20230401062YY, 20230204019YY, 20230401075YY, 2023C027-3, 2022JP06)
  • Jilin Provincial Development and Reform Commission program (82003985, JLPZGF-2020-107, 202310199001, 202310199051X, 20210204013YY, 20230401062YY, 20230204019YY, 20230401075YY, 2023C027-3, 2022JP06)
  • Changchun University of Chinese Medicine postgraduate training innovation demonstration project (82003985, JLPZGF-2020-107, 202310199001, 202310199051X, 20210204013YY, 20230401062YY, 20230204019YY, 20230401075YY, 2023C027-3, 2022JP06)

This publication has 189 references indexed in Scilit: